Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsRecovery & Healing43-AA (Tβ4) vs. 7-AA (TB-500) Blend / Stack

Thymosin Beta-4 (Full-Length 43-AA) vs. TB-500: Complete Protocol Guide

Also known as: Tβ4 (43-AA), Timbetasin, RGN-259, Thymosin Beta-4 vs. TB-500 (Ac-LKKTETQ)

Dose Range
500–1500 mcgResearch range
0Typical research window: 500–1500 mcg1800 mcg

Studied in published research — not a medical recommendation. Primary protocol (Full-Length 43-AA Thymosin Beta-4 Daily Tissue & Anti-Fibrotic Protocol): 500 mcg – 1,500 mcg (0.5–1.5 mg), Once daily.

Protocol at a Glance
How Often
Daily

Once daily

A Typical Run
4–6 weeks

Research-reported range (no primary dosing study). Daily dosing leverages the shorter plasma half-life of intact 43-AA Tβ4 and maintains steady Ac-SDKP anti-fibrotic cleavage

How It's Taken
Vial

Subcutaneous injection

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 500 mcg20 units
High end: 1500 mcg60 units

All U-100: 100 units = 1 mL. 10 doses in the vial at the low end (3 doses at the high end).

Track the doses you run

Save Thymosin Beta-4 (Full-Length 43-AA) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Full-Length 43-AA Endogenous Regenerative Protein (Timbetasin / TMSB4X, 4,963 Da)
Administration Route
Under-the-skin injection (Subcutaneous injection)
2026 FDA & 503A Status
Active Phase 2/3 human clinical trials in 2026; not yet FDA-approved for commercial prescription or 503A bulk pharmacy compounding. Sold strictly as an analytical laboratory reference standard.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

Thymosin Beta-4 (Full-Length 43-AA, MW 4,963 Da, Timbetasin / RGN-259) is the complete endogenous regenerative polypeptide containing both the N-terminal Ac-SDKP anti-fibrotic tetrapeptide (residues 1–4) and the central G-actin binding domain (residues 17–23, LKKTETQ), whereas true TB-500 (MW 889 Da) isolates only the 7-AA Ac-LKKTETQ fragment.

Best evidence for

Corneal/dermal wound repair (Phase 3 RGN-259), angiogenesis, and Ac-SDKP anti-fibrotic organ protection

Weakest evidence for

Unverified vendor vials that conflate 43-AA Tβ4 (4,963 Da) with 7-AA TB-500 (889 Da) without LC-MS mass spec verification

Pharma equivalent

RGN-259 / Timbetasin (RegeneRx — Phase 3 Ophthalmic/Dermal)

Studies on file

3 (0 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Thymosin Beta-4 (Full-Length 43-AA) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

First isolated from thymus extract by Allan Goldstein and colleagues, Thymosin Beta-4 (TMSB4X) is the primary intracellular G-actin sequestering peptide in mammalian tissue. When tissue injury occurs, platelets and macrophages release full-length 43-AA Tβ4 into the extracellular matrix. Full-length Tβ4 drives repair through multiple distinct domains: residues 1–4 (Ac-SDKP) are cleaved by prolyl oligopeptidase to exert potent anti-fibrotic, anti-inflammatory, and cardioprotective effects; residues 17–23 (LKKTETQ, the sequence sold as true TB-500) bind actin and promote endothelial/keratinocyte migration and angiogenesis; and the C-terminal region supports hair follicle stem cell and dermal matrix remodeling.

Mechanisms of Action

  • Residues 17–23 (LKKTETQ) sequester monomeric G-actin and stimulate endothelial, myoblast, and keratinocyte cell migration and angiogenesis
  • Residues 1–4 (N-terminal Ac-SDKP tetrapeptide, present ONLY in full-length 43-AA Tβ4) inhibit TGF-β/Smad3 organ fibrosis and suppress NF-κB macrophage inflammation
  • Up-regulates VEGF, laminin-5, and matrix metalloproteinase balance for scarless dermal, corneal, and tendon remodeling
  • Activates epicardial progenitor cells and hair follicle bulge stem cells

Common Ratios, Vial Formats & Dosing Breakdown

Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.

Open in Blend Calculator
43-AA (Tβ4) vs. 7-AA (TB-500)

Full-Length Thymosin Beta-4 (43-AA, 4,963 Da) vs. TB-500 Fragment (7-AA Ac-LKKTETQ, 889 Da)

Vial / Stack Breakdown

5 mg or 10 mg Lyophilized Vial (Check LC-MS Mass Spec on COA)

Typical Dosing & Syringe Draw

Full-Length Tβ4: 500 mcg – 1.5 mg SubQ daily · 7-AA TB-500 Fragment: 2.0–2.5 mg SubQ 2x/week

Why this ratio: How to verify what is in your vial: Check the mass spectrometry (LC-MS) molecular weight on your vendor’s Janoshik or MZ Biolabs COA. ~4,963 Da = Full-Length 43-AA Thymosin Beta-4; ~889 Da = 7-AA Ac-LKKTETQ (TB-500 fragment).

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Full-Length 43-AA Thymosin Beta-4 Daily Tissue & Anti-Fibrotic Protocol
reported protocol
500 mcg – 1,500 mcg (0.5–1.5 mg)Once daily4–6 weeks (followed by 2–4 week break)Subcutaneous injectionclinical trial—
Synergistic BPC-157 + Full-Length Tβ4 Recovery Stack
reported protocol
500 mcg BPC-157 + 500 mcg Full-Length Tβ4Once daily4–8 weeksSubcutaneous injectionhuman—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (Thymosin Beta-4 (Full-Length 43-AA))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Always inspect the LC-MS molecular weight on your vendor’s COA to confirm whether the vial contains 43-AA Tβ4 (~4,963 Da) or 7-AA Ac-LKKTETQ (~889 Da)
  • •Prohibited at all times in WADA-tested competition under Section S2.2 (Thymosin-β4 and its derivatives e.g. TB-500)
  • •Contraindicated in active malignancy due to pro-angiogenic and cell-migration signaling
  • •Removed from the FDA 503A Category 2 compounding list; available in the US as an analytical research reference standard
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Thymosin Beta-4 (Full-Length 43-AA), baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.